Enjaymo re-treatment deemed safe, effective in Japanese OLE study
Restarting Enjaymo (sutimlimab) after stopping it for up to four months was generally safe and brought blood markers of cold agglutinin disease (CAD) back to levels before its cessation. These are the findings of a Japanese open-label extension (OLE) study wherein seven CAD patients who completed one of…